Table 2: KIR receptor-HLA ligand association among cytomegalovirus and noncytomegalovirus infected renal transplantation cases.
| HLA | KIR | CMV | Non-CMV | p-value | O.R. | 95% CI |
| C1/C1 | KIR2DL2+ | 6/14 (42.8%) | 69/111 (62.1%) | 0.2462 | 0.45 | 0.14-1.40 |
| KIR2DL3+ | 7/22 (31.8%) | 64/200 (32.0%) | 1.0000 | 0.99 | 0.38-2.55 | |
| KIR2DS2+ | 3/10 (30.0%) | 27/82 (32.9%) | 1.0000 | 0.87 | 0.20-3.64 | |
| KIR2DS3+ | 2/9 (22.2%) | 27/72 (37.5%) | 0.4783 | 0.47 | 0.09-2.46 | |
| C2/C2 | KIR2DL1+ | 3/24 (12.5%) | 38/226 (16.8%) | 0.7751 | 0.70 | 0.20-2.49 |
| KIR2DS1+ | 6/10 (6.0%) | 42/101 (41.5%) | 0.3243 | 2.10 | 0.55-7.93 | |
| C1/C2 | KIR2DL2+ | 5/14 (35.7%) | 30/111 (27.0%) | 0.5332 | 1.50 | 0.46-4.83 |
| KIR2DL3+ | 8/22 (36.3%) | 70/200 (35%) | 1.0000 | 1.06 | 0.42-2.65 | |
| KIR2DS2+ | 5/10 (50.0%) | 32/82 (39.0%) | 0.5158 | 1.56 | 0.41-5.83 | |
| KIR2DS3+ | 4/9 (44.4%) | 30/72 (41.6%) | 1.0000 | 1.12 | 0.27-4.52 | |
| KIR2DL1+ | 10/24 (41.6%) | 81/226 (35.8%) | 0.6566 | 1.27 | 0.54-3.01 | |
| KIR2DS1+ | 4/10 (4.0%) | 36/101 (35.6%) | 0.7451 | 1.20 | 0.31-4.54 | |
| Bw4/Bw4 | KIR3DL1+ | 12/21 (57.1%) | 152/206 (73.7%) | 0.1255 | 0.47 | 0.18-1.18 |
| KIR3DS1+ | 9/15 (60.0%) | 69/135 (51.1%) | 0.5926 | 1.43 | 0.48-4.25 | |
| Bw6/Bw4 | KIR3DL1+ | 9/21 (42.8%) | 54/206 (26.1%) | 0.1255 | 2.11 | 0.84-5.29 |
| KIR3DS1+ | 6/15 (40.0%) | 66/135 (48.8%) | 0.5926 | 0.69 | 0.23-2.06 | |
| Combinatorial Analysis | ||||||
| Bw4/4 + Bw4/6 | KIR3DL1+ | 14(52%) | 149(75%) | 0.0201* | 0.60 | 0.40-0.92 |
| KIR3DS1+ | 10(42%) | 73(39%) | 0.4619 | 1.20 | 0.75-1.92 | |
| Bw4/4 + Bw6/6 | KIR3DL1+ | 9(36%) | 91(45%) | 0.3534 | 0.78 | 0.49-1.26 |
| KIR3DS1+ | 7(29%) | 41(20%) | 0.1744 | 1.52 | 0.87-2.65 | |
*=p< 0.05 & statistically significant. No significance was obtained for HLA C1/ C1 + C1/C2, HLA C2/C2 + C1/C2 and HLA C1/C1 + C2/C2 combinations when compared with their respective KIR receptors.